Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D Global BiotechROCO:6808 -1.72%81 Days Payable is 23.29 as of Jun. 2026, which is 40% below its 10-year median of 38.86. GuruFocus rates ROCO:6808 with a GF Score™ of 81/100 and a GF Value™ of NT$36.99 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 708 Biotechnology companies, 3D Global Biotech ranks worse than 95.34% on this metric.
The historical rank and industry rank for 3D Global Biotech's Days Payable or its related term are showing as below:
ROCO:6808'
s Days Payable Range Over the Past 10 Years
Min: 10.67 Med: 38.86 Max: 66.01
Current: 10.67
During the past 9 years, 3D Global Biotech's highest Days Payable was 66.01. The lowest was 10.67. And the median was 38.86.
ROCO:6808's Days Payable is ranked worse than 95.34% of 708
companies
in the Biotechnology industry
Industry Median: 111.165
vs ROCO:6808: 10.67
3D Global Biotech's Days Payable
declined
from Jun. 2025 (83.92) to Jun. 2026 (23.29).
It may suggest that 3D Global Biotechaccelerated paying its suppliers.
The historical data trend for 3D Global Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6808 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, 3D Global Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Global Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Global Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where 3D Global Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
3D Global Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Global Biotech (ROCO:6808) has a Days Payable of 23.29 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 3D Global Biotech and its competitors. This is 40% below median its historical median of 38.86. Over the past decade, 3D Global Biotech's Days Payable has ranged from 10.67 to 66.01. According to the industry distribution chart, 3D Global Biotech ranks #675 out of 708 companies in the Biotechnology industry, placing it in the top 95.3%.
Is 3D Global Biotech's Days Payable too high?
3D Global Biotech's current Days Payable of 23.29 is 40% below median its 10-year median of 38.86. Over the past 10 years, this metric has ranged from a low of 10.67 to a high of 66.01. The Biotechnology industry median Days Payable is 111.17. 3D Global Biotech's value of 23.29 is 79% below this industry median. Based on the distribution chart, 3D Global Biotech ranks #675 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 3D Global Biotech has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Global Biotech ranks #675 out of 708 companies for Days Payable. This places 3D Global Biotech in the lower half of its industry. The industry median Days Payable is 111.17. 3D Global Biotech's value of 23.29 is 79% below this benchmark. Historically, 3D Global Biotech's own Days Payable has ranged from 10.67 to 66.01 over the past decade. While the company's 10-year median is 38.86 vs. the industry median of 111.17, 3D Global Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Global Biotech's current Days Payable of 23.29 is 79% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 3D Global Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Global Biotech's current Days Payable is 23.29, which is 40% below median its own 10-year median of 38.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$36.99, compared to a current price of NT$31.45 — trading 15% below its estimated fair value. The current Days Payable is 23.29, which is 40% below median its 10-year median of 38.86 and 79% below the Biotechnology industry median of 111.17. 3D Global Biotech's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current Days Payable is 23.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Global Biotech stock appears to be undervalued.
The current stock price of NT$31.45 is trading 15% below its estimated GF Value™ of NT$36.99.
GuruFocus considers 3D Global Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6808:
Days Payable: 23.29 (40% below median its 10-year median of 38.86)
GF Value™: NT$36.99 vs. price of NT$31.45 (15% below fair value)
Industry Position: 79% below the Biotechnology median (#675 of 708)
No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
81GF Score
Get the complete analysis for ROCO:6808
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6808 has been successfully added to your 
